BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12369610)

  • 1. Clinical utility of milnacipran in comparison with other antidepressants.
    Bisserbe JC
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S43-50. PubMed ID: 12369610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milnacipran. A review of its use in depression.
    Spencer CM; Wilde MI
    Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of milnacipran: an overview.
    Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study.
    Fukuchi T; Kanemoto K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese experience with dual-action antidepressants.
    Tajima O
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-42. PubMed ID: 12369609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
    Kasper S; Pletan Y; Solles A; Tournoux A
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing antidepressant treatment: efficacy and tolerability.
    Deakin B; Dursun S
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-24. PubMed ID: 12369607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Applications and safety of modern antidepressants in patients with liver diseases].
    Dubarek W; Kucia K
    Wiad Lek; 2007; 60(1-2):28-33. PubMed ID: 17607965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.
    Nakagawa A; Watanabe N; Omori IM; Barbui C; Cipriani A; McGuire H; Churchill R; Furukawa TA;
    CNS Drugs; 2008; 22(7):587-602. PubMed ID: 18547127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
    Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
    Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.
    Steen A; Den Boer JA
    Int Clin Psychopharmacol; 1997 Sep; 12(5):269-81. PubMed ID: 9466161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled comparison of milnacipran and fluoxetine in major depression.
    Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J
    Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ejaculation after defecation without orgasm induced by milnacipran.
    Yoshida K; Higuchi H; Takahashi H; Shimizu T
    J Neuropsychiatry Clin Neurosci; 2004; 16(4):544. PubMed ID: 15616184
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacology and pharmacokinetics of milnacipran.
    Puozzo C; Panconi E; Deprez D
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S25-35. PubMed ID: 12369608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
    Clerc G;
    Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of milnacipran by risperidone in treatment for major depression.
    Tani K; Takei N; Kawai M; Suzuki K; Sekine Y; Toyoda T; Minabe Y; Mori N
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):55-8. PubMed ID: 14731310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.